This nationwide follow-up study concerns the pattern of malignant tumours in a cohort of patients with psoriasis, at an average of 9.3 years after discharge from hospital. The study confirms that the significantly increased risk of cancer in these patients, amounting to 1.4 times that in the general population, is mainly due to cancer of the skin and lung in both sexes and cancer of the pharynx and larynx in men. Non-melanoma skin cancer is the most common malignancy, occurring in 196 of 795 patients with cancer: standardized incidence ratio (SIR, the ratio of observed to expected cancers) 2.4 for men and 2.6 for women. This means an overall lifetime risk (up to the age of 75 years) of 14.1%. In particular, squamous cell carcinoma (SCC) by itself (n = 45, SIR 3.9 for men and 4.7 for women), cancer in multiple sites (SIR 5.9 for basal cell carcinoma (BCC) and 11.7 for (SCC) and SCC on the lower extremities (SIR 18.0) are frequent. Women run the highest risk of BCC in the age range 20-40 years, while men in the age range 30-60 years run a particularly high risk of SCC. When monitoring patients extensively treated for psoriasis, this aberrant pattern of cancer should be taken into account.

No abstract

No abstract

Three hundred and four patients with non-psychogenic erectile dysfunction (ED) completed a dose assessment phase with intracavernosal injection utilizing 25 mg vasoactive intestinal polypeptide (VIP) combined with phentolamine mesylate 1.0 mg (VIPaP-1) or 2.0 mg (VIPaP-2) in an autoinjector for a response rate of 83.9%. In a sub-group of 183 patients who withdrew from one or more previous ED therapies, 82% responded with an erection suitable for intercourse. One hundred and ninety-®ve patients were subsequently treated in a placebo controlled phase. 75.1% responded to VIPaP-1, 12% to placebo (P`0.001); 66.5% responded to VIPaP-2, 10.3% to placebo (P<0.001), with the median duration of erection of 54 min. The principal adverse event was transient facial¯ushing in 2770 injections (33.9%). There was no pain post injection and two episodes of priapism (0.05%). Only nine patients withdrew because of adverse events. Over 85% and 95% of patients were satis®ed with the drug and auto-injector, respectively. Over 81% of patients and 76% of partners reported an improved quality of life.

No abstract